Sarepta Therapeutics Announces Second Quarter 2024 Financial ...

Sarepta Therapeutics to Announce Third Quarter 2024 Financial ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results.

Sarepta Therapeutics Announces Third Quarter 2022 Financial

The holders exchanged $150.6 million in aggregate principal value of 2024 Notes held by them plus accrued interest of $0.8 million for an ...

Sarepta Therapeutics Announces Second Quarter 2023 Financial ...

Following approval on June 22 , the first patient received commercially reimbursed ELEVIDYS (delandistrogene moxeparvovec-rokl), ...

Aclaris Therapeutics Reports Second Quarter 2024 Financial ...

Revaluation of contingent consideration resulted in a $3.0 million loss for the six months ended June 30, 2024 compared to a gain of $2.3 million for the prior ...

Sarepta Therapeutics, Inc. Q2 2024 Earnings Conference Call ...

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will ...

Sarepta Stock Price Today | NASDAQ: SRPT Live - Investing.com

Please try another search. Get 55% Off. Sign In; Free Sign Up. English ... Nov 06, 2024. Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results.

Sarepta Therapeutics Announces Fourth Quarter and Full-Year

Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in ...

Pfizer: One of the world's premier biopharmaceutical companies

Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView

Strategic Investment: In August 2023, Lexeo announced a strategic investment from Sarepta Therapeutics, Inc. to explore collaboration ...

Endpoints News – Biotech and pharma business news, with a focus ...

Biotech and pharma business news, with a focus on the science, people and money that drive the industry.

Sarepta Therapeutics Announces Fourth Quarter and Full-Year ...

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments · $150.3 million , compared ...

Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The ...

Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ...

Promising Phase 1/2 Study and Strong Financials Drive Buy Rating ...

... Pharma, Avidity Biosciences, and Sarepta Therapeutics ... Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates.

Health Care Roundup: Market Talk - WSJ

The pharmaceutical-and-agricultural group lowered its profit target for 2024 after tough market conditions hit its crop-science division, ...

Zevra Therapeutics Reports Second Quarter 2024 Financial Results ...

Net revenue for Q2 2024 was $4.4 million, compared to net revenue of $8.5 million in Q2 2023. ... In addition, cost of goods sold was inflated during the quarter ...

Sarepta Therapeutics (NASDAQ:SRPT) Rating Increased to ...

EP Wealth Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 ...

Sarepta Therapeutics, Inc. Q2 3024 Earnings Conference Call ...

... fourth quarter of 2024, the commencement of a clinical study for SRP-9005 in early 2025, finishing enrollment for ENVISION in 2025, and ...

Events & Presentations | Sarepta Therapeutics, Inc.

Archived Events and Presentations ; 08/07/24 at 4:30 PM EDT. Sarepta Therapeutics Second Quarter 2024 Earnings Call · Click here for webcast · 2Q 2024 Forward ...

Form 10-Q for Sarepta Therapeutics INC filed 08/07/2024

See accompanying notes to unaudited condensed consolidated financial statements. 5. Page 6. SAREPTA THERAPEUTICS, INC. CONDENSED CONSOLIDATED ...

Sarepta Therapeutics Announces U.S. FDA Acceptance of an ...

Priority review granted, with a review goal date of June 21, 2024 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 16, 2024-- Sarepta Therapeutics, ...